{
    "pmcid": "9512078",
    "qa_pairs": {
        "How does the VHH-IgA1.1 nanobody enhance mucosal immunity against SARS-CoV-2?": [
            "By being fused with the IgA Fc region",
            "By being delivered intravenously",
            "By targeting the N-terminal domain",
            "By being produced in mammalian cells"
        ],
        "What is the primary target of the VHH-IgA1.1 nanobody in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD)",
            "The N-terminal domain (NTD)",
            "The S2 subunit",
            "The fusion peptide"
        ],
        "What is the production method for VHH-IgA1.1 that maintains its potency while being cost-effective?": [
            "Production in yeast (Pichia pastoris)",
            "Production in bacterial cells",
            "Production in insect cells",
            "Production in mammalian cells"
        ],
        "What method of delivery is proposed for VHH-IgA1.1 to confer mucosal immunity?": [
            "Intranasal delivery",
            "Intravenous injection",
            "Oral administration",
            "Subcutaneous injection"
        ],
        "Which specific residues on the SARS-CoV-2 spike protein are critical for the neutralizing activity of VHH-IgA1.1?": [
            "Y449, Y453, and Y473",
            "N501, D614, and P681",
            "E484, K417, and L452",
            "T478, F490, and Q493"
        ]
    }
}